Hudson Bay Capital Management’s Travere Therapeutics TVTX Stock Holding History

Hudson Bay Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$194K	Buy	+6,520	New	+$195K	﹤0.01%	1109
2024 Q4	–	Sell	-125,000	Closed	-$1.75M	–	1116
2024 Q3	$1.75M	Buy	125,000 +80,439	+181%	+$838K	0.01%	584
2024 Q2	$366K	Buy	+44,561	New	+$300K	﹤0.01%	651
2023 Q3	–	Sell	-444,031	Closed	-$6.82M	–	968
2023 Q2	$6.82M	Buy	+444,031	New	+$8.08M	0.05%	249
2019 Q3	–	Sell	-56,779	Closed	-$1.14M	–	484
2019 Q2	$1.14M	Buy	+56,779	New	+$1.12M	0.03%	320

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hudson Bay Capital Management's TVTX Position: Q1 2026 in Review

Hudson Bay Capital Management opened a new position in Travere Therapeutics (TVTX) in Q1 2026: 6,520 shares worth $194K. The stake represents ﹤0.01% of the portfolio and ranks #1109 among its holdings. This is a return to the name: Hudson Bay Capital Management previously reported a position in TVTX as recently as Q3 2024.

Hudson Bay Capital Management first reported a position in TVTX in Q2 2019 and has held it in 5 quarters since. The position peaked at $6.82M in Q2 2023. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Hudson Bay Capital Management held 6,520 shares of Travere Therapeutics worth $194K as of Q1 2026.
Travere Therapeutics was a new Hudson Bay Capital Management position in Q1 2026.
Travere Therapeutics made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q1 2026, its #1109 holding.
Hudson Bay Capital Management first reported a position in Travere Therapeutics in Q2 2019 and has held it in 5 quarters since.
Hudson Bay Capital Management's Travere Therapeutics position peaked at $6.82M in Q2 2023.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.